investing.comNov 9$CRMD

CorMedix to acquire Heron assets for $145M cash plus stock

CorMedix (CRMD) will acquire Heron Therapeutics (HRTX) assets for $145M in cash, plus 14.6M shares, with potential earn-outs. The deal adds four commercial-stage products to CorMedix's portfolio and is valued at ~$222.6M. CorMedix expects $45-$60M in annual cost synergies by 2027 and pro forma 2026 revenue of $465-$490M. The transaction requires stockholder and regulatory approval, with an expected close in Q1 2027.

Original reporting

investing.com

Published Nov 9, 2026, 12:16 PM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Nov 9, 2026, 12:27 PM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefMergers & acquisitions

Primary signal

$CRMD

Bullish

high confidence

Mentioned

$CRMD · $HRTX

Relevance

8/10

AlphAI data visualization · based on investing.com

Decision brief

The 30-second read

$CRMDBullishHigh

Why it matters

The acquisition is expected to boost CorMedix's revenue base and cost efficiency, while providing Heron shareholders with immediate value.

Market read

A material M&A deal in the biotech space that could move both CRMD and HRTX stocks on the day of announcement.

What to watch

Potential regulatory hurdles and integration risk could delay expected cost savings.

Relevance 8/10Novelty 8/10Timing: today

Background

The announcement follows CorMedix's recent $150M senior secured term loan and reflects its strategy to broaden its commercial portfolio.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$CRMDBullishHigh confidence

Context

CorMedix announced acquisition of Heron assets for $145M cash plus stock, adding four commercial-stage products and synergies.

Expected impact

upward pressure as investors price in the acquisition premium and expected synergies.

Evidence & confidence

The transaction adds $465-$490M pro forma revenue and $45-$60M cost synergies, a material catalyst for the stock.

$HRTXBullishHigh confidence

Context

Heron Therapeutics will be acquired, remaining public with $2.3B net operating loss carryforwards.

Expected impact

upward pressure as the market prices the acquisition premium and future cash consideration.

Evidence & confidence

The announced cash component and stock issuance represent a premium to current market price.

Market effects

Sector

Strengthens the biotech/oncology sector by consolidating niche nausea‑vomiting therapies.

Regional

U.S. biotech market may see modest uplift as deal highlights M&A activity.

Global

Limited to investors focused on specialty pharma and biotech M&A.

Counterpoint

What could challenge this read

Deal may overpay for Heron assets, diluting existing shareholders if synergies fall short.

Key entities

Company
CorMedix Therapeutics
Acquirer, NASDAQ:CRMD
Company
Heron Therapeutics Inc.
Target, NASDAQ:HRTX

Read at source ← All news

$CRMDHighAI 8/10

CorMedix to Acquire Heron Assets, Adding Four Products and Targeting Up to $60 Million in Savings

CorMedix (CRMD) will acquire assets from Heron, adding four products and aiming for $60M in savings. Heron may receive up to $55M in additional payments tied to ZYNRELEF's 2028 sales. CorMedix will fund the deal with $70M in cash and a $150M loan. Heron's convertible debt holders will convert debt into CorMedix stock. CorMedix plans to relaunch SUSTOL and focus on APONVIE, with a potential FDA approval for an undisclosed injectable product in 2027.

finance.yahoo.comNov 10

$CRMDHighAI 8/10

CorMedix stock maintains outperform rating on Heron acquisition

Citizens reiterated an Outperform rating and $19.00 price target on CorMedix (CRMD). The company agreed to acquire Heron Therapeutics' assets for $225M, expecting to close in Q1 2027. CRMD reported Q2 2026 earnings of $0.29/share on $101.9M revenue, beating estimates. Analysts highlight strategic fit, revenue diversification, and strong financials.

investing.comNov 10

$CRMDMed

Key facts: CorMedix to Acquire Heron’s Four Commercial Assets for $145M, Shares and Earn-Outs

CorMedix (CRMD) will acquire four commercial products from Heron Therapeutics for $145M in cash, 14.6M shares, and up to $55M in earn-outs. The deal, expected to close in Q1 2027, includes therapies for post-surgery pain, nausea, and chemotherapy-related nausea. CorMedix plans to sell these products through its existing network.

tradingview.comNov 10

$HRTXHigh

Heron Therapeutics Reports Q3 Revenue Of $35.3 Mln; Agrees To Sell Assets To CorMedix

Heron Therapeutics (HRTX) reported Q3 2026 revenue of $35.3M, down from $38.2M YoY. Acute Care revenue grew 22.5% YoY, while Oncology Supportive Care declined. Heron agreed to sell all assets to CorMedix (CRMD) for $145M cash, 14.58M CRMD shares, and up to $55M in earn-outs. The deal is expected to close in Q1 2027. HRTX and CRMD shares are up 30.00% and 2.07% respectively.

rttnews.comNov 9

$CRMDHighAI 9/10

CorMedix, Heron Strike $223 Mln Upfront Asset Deal; Closing Expected In 2027; Stock Up

CorMedix (CRMD) will acquire Heron's (HRTX) assets for $222.6M upfront, including cash and stock, with potential earn-outs. The deal adds four commercial-stage products to CorMedix's portfolio, expected to close in 2027. CorMedix anticipates earnings accretion and cost synergies, while Heron will remain public and evaluate future opportunities. Both stocks rose on the news.